RecruitingModerate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Eligible age
6–17 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Sponsor: UCB Biopharma SRL
You may qualify if…
- ✓ Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the informed consent/assent according to local regulation
- ✓ Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit
- ✓ Study participant meets the following at both the Screening and Baseline Visits:
- ✓ 1. Body surface area (BSA) affected by PSO ≥10%
- ✓ 2. . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
- ✓ 3. . Psoriasis Area and Severity Index (PASI) score ≥12 OR
- ✓ PASI score ≥10 plus at least 1 of the following:
- ✓ i) Clinically relevant facial involvement ii) Clinically relevant genital involvement iii) Clinically relevant hand and foot involvement
You may not qualify if…
- ✕ Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17
- ✕ Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
- ✕ Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
- ✕ History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
- ✕ Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
- ✕ Study participant has previously received bimekizumab
- ✕ Study participant has previously received ustekinumab
- ✕ Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
Where it's recruiting
California
Fountain Valley · Los Angeles · Northridge
Florida
Miami
Indiana
Indianapolis
New York
Kew Gardens
South Carolina
Charleston
Texas
Arlington · Dallas
Source: ClinicalTrials.gov · NCT06425549 · last updated 2026-05-22